AbbVie Inc. EV/Operating CF

EV/Operating CF of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Operating CF growth rates and interactive chart. A valuation metric that measures the enterprise value of a company compared to its operating cash flow. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low EV/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/Operating CF of AbbVie Inc. is 11.82 (as of December 30, 2019)
  • EV/Operating CF for the quarter ending December 30, 2019 was 11.82 (a 13.57% increase compared to previous quarter)
  • Year-over-year quarterly EV/Operating CF increased by 7.69%
  • Annual EV/Operating CF for 2019 was 11.82 (a -8.95% decrease from previous year)
  • Annual EV/Operating CF for 2018 was 12.98 (a -29.97% decrease from previous year)
  • Annual EV/Operating CF for 2017 was 18.54 (a -0.85% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Operating CF of AbbVie Inc.

Most recent EV/Operating CFof ABBV including historical data for past 10 years.

Interactive Chart of EV/Operating CF of AbbVie Inc.

AbbVie Inc. EV/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 11.82 10.41 10.48 10.98 11.82
2018 12.98 13.89 15.78 16.5 12.98
2017 18.54 19.36 20.52 19.21 18.54
2016 18.7 17.73 15.97 14.31 18.7
2015 15.86 22.58 28.47 22.33 15.86
2014 31.27 17.98 17.54 15.3 31.27
2013 14.16 12.8 11.24 12.27 14.16
2012 9.94 9.94 9.94 9.94 9.94
2011 9.94 9.94 9.94 9.94 9.94
2010 9.94
2009 9.94

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.